Cover Image
市場調查報告書

第一型糖尿病 (幼年型糖尿病) :開發中產品分析

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232787
出版日期 內容資訊 英文 621 Pages
訂單完成後即時交付
價格
Back to Top
第一型糖尿病 (幼年型糖尿病) :開發中產品分析 Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 621 Pages
簡介

所謂第一型糖尿病 (幼年型糖尿病) ,是胰臟中斷生產胰島素的自體免疫疾病。由於人體的免疫系攻擊、破壞胰臟內部的胰島素生產細胞 (β細胞)而發病。主要的易罹病素質、有先天性疾病和家族病史、胰臟疾病、感染疾病等。主要的前兆、症狀,有嚴重的乾渴和頻繁的尿意、極度的空腹感、體重減少、倦怠感、易怒,非日常性行動等。在治療時,必須改善生活習慣和定時藥物治療。

本報告提供全球第一型糖尿病 (幼年型糖尿病) 治療藥的開發中產品的開發情形的相關分析,產品開發、上市的最新趨勢和臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

第一型糖尿病 (幼年型糖尿病)的概要

治療藥的開發

第一型糖尿病 (幼年型糖尿病):企業開發中的治療藥

第一型糖尿病 (幼年型糖尿病):大學/機關研究中的治療藥

第一型糖尿病 (幼年型糖尿病):開發中產品概況

第一型糖尿病 (幼年型糖尿病):企業開發中的產品

第一型糖尿病 (幼年型糖尿病):大學/機關研究中的產品

第一型糖尿病 (幼年型糖尿病的)治療藥開發作的企業

第一型糖尿病 (幼年型糖尿病):治療藥的評估

藥物簡介

第一型糖尿病 (幼年型糖尿病):最近的開發平台趨勢

第一型糖尿病 (幼年型糖尿病):暫停中的計劃

第一型糖尿病 (幼年型糖尿病):開發中止的產品

第一型糖尿病 (幼年型糖尿病):產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8770IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 29, 21, 3, 106, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 29 and 6 molecules, respectively.Type 1 Diabetes (Juvenile Diabetes).

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Type 1 Diabetes (Juvenile Diabetes) Overview
  • Therapeutics Development
  • Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies
  • Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Investigation by Universities/Institutes
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline Products Glance
  • Type 1 Diabetes (Juvenile Diabetes) - Products under Development by Companies
  • Type 1 Diabetes (Juvenile Diabetes) - Products under Investigation by Universities/Institutes
  • Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
  • Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment
  • Drug Profiles
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products
  • Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016
  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AbGenomics International, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH and Co KG, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Alteogen Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ambrx, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AntriaBio, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corporation, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by APT Therapeutics, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Athersys, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Limited, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biogenomics Limited, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLineRx, Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioTherapeutics Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Carlina Technologies SAS, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ConjuChem, LLC, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by enGene, Inc, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by EpiVax, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Escape Therapeutics, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corporation, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Geropharm, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Grifols, S.A., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Iltoo Pharma, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ImmusanT, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Innopharmax Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corporation, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Islet Sciences, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Private Limited, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lonestar Heart, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MacroGenics, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production S.p.A., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co., Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co., Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MidaSol Therapeutics LP, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis Inc, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by OSE Immunotherapeutics, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Parvus Therapeutics, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy Inc, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corporation, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma, LLC, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corporation, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by SEKRIS Biomedical, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Semma Therapeutics Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sevion Therapeutics, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Strongbridge Biopharma plc , H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes, LLC, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Limited, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by UCB SA, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Unicyte AG, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by United Therapeutics Corporation, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Visionary Pharmaceuticals, Inc., H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corporation, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..1), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..2), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..3), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..4), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..5), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..6), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..7), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..8), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..9), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..10), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..11), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..12), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products (Contd..1), H2 2016
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016
  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top